Streetbeat News

Analyst Ratings

BEAM

Beam Therapeutics reported Q2 losses of $(1.08) per share, beating the analyst consensus estimate of $(1.42) by 23.94%. The company also reported quarterly sales of $20.12 million, surpassing the analyst consensus estimate of $18.05 million by 11.45%. This represents a 20.80% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:33 am

SWAV

Needham analyst Mike Matson maintains a 'Buy' rating on ShockWave Medical (NASDAQ:SWAV) and raises the price target from $325 to $330.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:33 am

PSTX

HC Wainwright & Co. analyst Arthur He has reiterated a 'Buy' rating on Poseida Therapeutics (NASDAQ:PSTX) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:32 am

ARMK

Aramark reported Q3 adjusted earnings of $0.36 per share, beating the analyst consensus estimate of $0.33 by 9.09%. This is a 44% increase from the same period last year. The company also reported quarterly sales of $4.75 billion, beating the analyst consensus estimate of $4.57 billion by 3.98%, a 15.10% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:31 am

ATXS

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Astria Therapeutics (NASDAQ:ATXS) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:31 am

ARCT

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:30 am

DAWN

HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:29 am

GTBP

HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on GT Biopharma (NASDAQ:GTBP) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:28 am

TNGX

HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Tango Therapeutics (NASDAQ:TNGX) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:23 am

SAGE

Needham analyst Ami Fadia has downgraded Sage Therapeutics from Buy to Hold.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 10:22 am